Evidence map›Paper›PMID 33880389›Full record

ArticleOpen forum infectious diseases2021

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy.

Ann W N Auma, Carey Shive, Sofi Damjanovska, Corinne Kowal, Daniel E Cohen, Debika Bhattacharya, Beverly Alston-Smith, Melissa Osborne, Robert Kalayjian, Ashwin Balagopal and 3 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Ann W N AumaDepartment of Pathology, VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Carey ShiveDepartment of Pathology, VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Sofi DamjanovskaDepartment of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Corinne KowalDepartment of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Daniel E CohenAbbVie Inc., North Chicago, Illinois, USA.
Debika BhattacharyaDivision of Infectious Diseases, Department of Medicine David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Beverly Alston-SmithDAIDS, National Institutes of Health, Bethesda, Maryland, USA.
Melissa OsborneDepartment of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Robert KalayjianDepartment of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Ashwin BalagopalJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Mark SulkowskiJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David WylesUniversity of Colorado School of Medicine, Denver, Colorado, USA.
Donald D AnthonyDepartment of Pathology, VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Case Western Reserve University · USJohns Hopkins Medicine · USMetroHealth Medical Center · USAbbVie (United States) · USNational Institutes of Health · USUniversity of California, Los Angeles · USUniversity of Colorado Denver · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
Microbiology and Immunology Training for HIV and HIV-Related Research in Uganda (MITHU)D43TW010319 · FIC · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, JOLOBA, MOSES LUTAAKOME · 2016 to 2025
$3.1M
Patient Oriented Research in Hepatitis C-infected Injection Drug UsersK24DA034621 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2012 to 2022
$1.2M
Role of IL-6 and IL-1b in immune dysfunction during aging, HIV, and HCV infectionIK2CX001471 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI SHIVE, CAREY LYNN · 2017 to 2021
–
Role of NK cells in control of HCV infection associated hepatocellular carcinomaI01BX001894 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI Donald D Anthony · 2013 to 2026
–
BLRD VA I01 BX001894CSRD VA I01 CX001791CSRD VA IK2 CX001471FIC NIH HHS D43 TW010319NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIDA NIH HHS K24 DA034621
6 · The paper itself

Abstract

backgroundImmune activation markers associate with morbidity and mortality in HIV and hepatitis C virus (HCV) infection. We investigated how T-cell and monocyte activation are related over the course of HCV direct-acting antiviral (DAA) therapy during HCV/HIV coinfection.

methodsPeripheral blood mononuclear cells from AIDS Clinical Trials Group (ACTG) A5329 participants and a single-site separate cohort treated with DAAs were analyzed for central memory (CM)/effector memory (EM) T-cell subsets, monocyte subsets, and cell activation (CD38 and HLA-DR expression) before, during, and after therapy.

resultsBefore therapy, classical and inflammatory monocyte subset HLA-DR expression positively correlated with absolute counts and frequencies of CD38

conclusionsDuring HCV/HIV coinfection, memory T-cell activation is associated with monocyte subset activation, consistent with related underlying mechanisms. Following therapy initiation, memory T-cell, but not monocyte, activation decreased. Residual CD4

Indexed as

DAA therapyhepatitis C and HIV coinfectionhumanimmunityinflammationmonocyteT cell

Identifiers

PMID33880389
PMCPMC8043262
OpenAlexW3129503124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.